VTP50469 is a potent and specific inhibitor of the Menin/KMT2A interaction with demonstrated activity against KMT2A-fusion leukemia [35] and NPM1-mutated leukemia, where it targets wild-type KMT2A [41, 45]. Here, KMT2A is linked to leukemia.